Sequencing.com Raises $5M in Venture Capital to Fund Breakthrough DTC DNA Technology
Sequencing logo
In the next 5 years, we expect that between 100 million and 2 billion human genomes will be sequenced. This capital raising allows us to rapidly expand our unique solutions that unlock the true value of genetic data and directly empower the individual
LOS ANGELES (PRWEB)
8 November 2022
Sequencing.com, the leader in direct-to-consumer DNA interpretation, has raised $5 million in venture capital funding. The funding is led by Lerer Hippeau and includes Red Sea Ventures, Global Founders Capital, XRC Labs, Correlation Ventures, Red Antler, Mucker Capital and Gaingels.
“Over the next 5 years, we expect that between 100 million and 2 billion human genomes will be sequenced. This capital raising allows us to rapidly expand our unique solutions that unlock the true value of genetic data and directly empower the individual,” said Dr. . Brandon Colby, CEO and founder of Sequencing.com. “We are extremely excited to be working with proven consumer-centric investors who support our broader mission to empower everyone to outsmart their genes.”
Builds on state-of-the-art DNA technology
The new round of funding will allow Sequencing.com to continue to build on and improve its DNA technology, which includes adding a 30x whole genome sequencing service with the fastest direct-to-consumer turnaround time. In addition, the company offers the largest marketplace for DNA analysis and reports in the world, with over 100 apps and growing.
“Sequencing.com’s offering makes whole-genome analysis accessible and affordable for the first time,” said Caitlin Strandberg, partner at Lerer Hippeau. “This development will usher in a new wave of personalized and preventive healthcare that prioritizes privacy and security. We look forward to seeing what the Sequencing.com team unlocks in terms of long-term discoveries that will impact how people understand themselves and their health and well-being.”
Sequencing.com has also recently upgraded its two popular proprietary applications, Genome Explorer and Next-Gen Rare Disease Screen. Genome Explorer is the first genome browser and search engine that allows customers to easily access information and the latest research relevant to their DNA data. The Next-Gen Rare Disease Screen gives customers the ability to screen their genome for the risk of thousands of rare diseases, conditions and traits.
Helping customers outsmart their genes
Dr. Colby saw the need for a direct-to-consumer DNA technology business model more than 15 years ago while practicing personalized preventive medicine in Los Angeles. The reactionary nature of healthcare in the United States led him to turn to the latest cutting-edge developments in genetic technology as the solution to the ongoing problem of animal and often ineffective medical intervention. In 2014, he founded Sequencing.com as a way to facilitate access to genetic services for all people.
“Understanding your own genome allows you to outsmart your genes and live a longer, healthier life,” said Dr. Colby. “We are now at a critical inflection point where whole-genome sequencing has become increasingly affordable for more people. Sequencing.com is the safe, secure place for everyone to store their genetic information and receive useful, lifelong guidance based on their DNA.”
————————————————– ——————
About Sequencing.com
Sequencing.com provides everything the customer needs to easily access and understand their genes. This includes free, unlimited storage of DNA data as well as unique tools and enhanced reports that transform DNA data into clear solutions for better health.
Their team consists of American doctors, geneticists, bioinformatics experts and software developers. While their backgrounds are diverse, they all share a passion for creating innovative solutions designed to help their customers live healthier, happier and longer lives. Learn more at Sequencing.com.
About Lerer Hippeau
Lerer Hippeau is an early stage venture capital firm founded and operated in New York City. Since 2010, they’ve invested in entrepreneurs who embody this city’s grit, tenacity and winning mindset – good people with good ideas who aren’t afraid to do hard things. Their portfolio includes more than 400 leading enterprise and consumer companies, including Guideline, MIRROR, Blockdaemon, K Health, Allbirds, ZenBusiness and Thrive. They are seasoned operators who invest early and stay in founders’ corners as they build iconic companies. Learn more at lererhippeau.com.
Share the article on social media or email:
